Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 15/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.39 |
| ▸ | PDE1A | P54750 | 3/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7906253 | 0.94 | PDE9A (0.53) | PDE9APDE5APDE1BPDE1APDE1C | |
| SCHEMBL471001 | 0.94 | PDE9A (0.54) | PDE9APDE5APDE1BPDE1APDE1C | |
| SCHEMBL471049 | 0.90 | PDE9A (0.51) | PDE9APDE5APDE1BPDE1APDE1C | |
| SCHEMBL1722631 | 0.87 | PDE9A (0.64) | PDE9APDE5APDE1B | |
| SCHEMBL14827029 | 0.86 | PDE9A (0.54) | PDE9APDE5APDE1BPDE1APDE1C | |
| SCHEMBL15365613 | 0.85 | PDE9A (0.49) | PDE9APDE5APDE1BPDE1APDE1C | |
| SCHEMBL7912528 | 0.85 | PDE9A (0.44) | PDE9APDE5APDE1BPDE1APDE1C | |
| SCHEMBL12043273 | 0.85 | PDE9A (0.55) | PDE9APDE5APDE1B | |
| SCHEMBL7902958 | 0.85 | PDE9A (0.55) | PDE9APDE5APDE1B | |
| SCHEMBL7898759 | 0.84 | PDE9A (0.34) | PDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901126-B2 | Substituted imidazo[1,5-A]quinoxalin-4-ones are useful for preventing or treating storage dysfunction, voiding dysfunction and bladder/urethral diseases | ASTELLAS PHARMA INC. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901126-B2 | Substituted imidazo[1,5-A]quinoxalin-4-ones are useful for preventing or treating storage dysfunction, voiding dysfunction and bladder/urethral diseases | ASTELLAS PHARMA INC. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8674096-B2 | Substituted imidazo[1,5-a]quinoxalin-4-ones as phosphodiesterase 9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20130296329-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296329-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130085134-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085134-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8357688-B2 | Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2013-01-22 | — | — | US | disclosed |
| US-8357688-B2 | Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2013-01-22 | — | — | US | disclosed |
| WO-2012033101-A1 | QUINOXALINE COMPOUND | アステラス製薬株式会社 (JP) | 2012-03-15 | — | — | WO | disclosed |
| EP-2404922-A1 | QUINOXALINE COMPOUNDS | Astellas Pharma Inc. (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-20110319385-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319385-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-12-29 | — | — | US | disclosed |
| WO-2010101230-A1 | QUINOXALINE COMPOUNDS | アステラス製薬株式会社 (JP) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085134-A1 | QUINOXALINE COMPOUND | PDE9A, PDE2A, PDE3A | PDE9A 1/4885PDE5A 4/4885PDE1B 30/4885 |
| US-20130296329-A1 | QUINOXALINE COMPOUND | PDE9A, PDE5A, PDE2A | PDE9A 1/4885PDE5A 2/4885PDE1B 33/4885 |
| US-20110319385-A1 | QUINOXALINE COMPOUND | PDE9A, PDE5A, PDE3A | PDE9A 1/4885PDE5A 2/4885PDE1B 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.